Please use this identifier to cite or link to this item:
|Title:||Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes : an approach for improved oral pharmacokinetics of Sorafenib||Authors:||Muhammad Adeeb Khan
Venkatraman, Subbu S.
Muhammad Farhan Sohail
|Keywords:||Engineering::Materials||Issue Date:||2018||Source:||Muhammad Adeeb Khan, Shaukat Ali, Venkatraman, S. S., Muhammad Farhan Sohail, Muhammad Ovais, Abida Raza. (2018). Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes : an approach for improved oral pharmacokinetics of Sorafenib. International Journal of Pharmaceutics, 542(1-2), 196-204. doi:10.1016/j.ijpharm.2018.03.023||Journal:||International Journal of Pharmaceutics||Abstract:||Sorafenib (SFN), a hydrophobic anticancer drug, has several limitations predominantly poor aqueous solubility and hepatic first-pass effect, limiting its oral delivery that results into several other complications. Present study aims to develop Sorafenib loaded polymersomes using poly butadiene block poly ethylene oxide (PB-b-PEO), an amphiphilic co-block polymer. Prior to drug loading, critical aggregate concentration (CAC) of polymer was calculated for stable formulation synthesis. The developed SFN loaded PB-b-PEO polymersomes (SFN-PB-b-PEO, test formulation) characterized by DLS and cryo-TEM showed particle size 282 nm, polydispersity (PDI) of less than 0.29 and membrane thickness of about 20 nm. SFN-PB-b-PEO polymersomes demonstrated encapsulation efficiency of 71% and showed sustained drug release up to 144 h. Formulation remained stable for 3 months in suspension form. In vitro cytotoxicity against HepG2 cells showed 1.7 folds improved toxicity compared to SFN suspension. In addition, oral administration of SFN-PB-b-PEO polymersomes in BALB/c mice showed increased Cmax and AUC0-96 by 1.7 and 2.77-fold respectively (p < 0.05) compared to those of SFN suspension (reference formulation). Findings suggest that the SFN-PB-b-PEO polymersomes can be a potential candidate for oral delivery of SFN.||URI:||https://hdl.handle.net/10356/141202||ISSN:||0378-5173||DOI:||10.1016/j.ijpharm.2018.03.023||Rights:||© 2018 Elsevier B.V. All rights reserved.||Fulltext Permission:||none||Fulltext Availability:||No Fulltext|
|Appears in Collections:||MSE Journal Articles|
Updated on Mar 10, 2021
Updated on Mar 7, 2021
Updated on Sep 17, 2021
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.